ImmuCell (NASDAQ:ICCC) Stock Price Passes Above Fifty Day Moving Average – What’s Next?

ImmuCell Corporation (NASDAQ:ICCC) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $9.55 and traded as high as $10.60. ImmuCell shares last traded at $10.34, with a volume of 37,793 shares changing hands.

Analyst Ratings Changes

A number of brokerages have commented on ICCC. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmuCell in a research report on Thursday, July 2nd. Wall Street Zen raised ImmuCell to a “strong-buy” rating in a research report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ImmuCell presently has a consensus rating of “Sell”.

ImmuCell Stock Performance

The company has a current ratio of 4.82, a quick ratio of 2.60 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $93.55 million, a price-to-earnings ratio of -172.30 and a beta of 0.56. The stock has a fifty day moving average price of $9.55 and a 200-day moving average price of $7.59.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $10.36 million for the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.

Insider Transactions at ImmuCell

In other news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of ImmuCell stock in a transaction on Thursday, June 18th. The shares were purchased at an average cost of $9.49 per share, for a total transaction of $75,920.00. Following the completion of the transaction, the chief executive officer directly owned 17,785 shares in the company, valued at approximately $168,779.65. This represents a 81.76% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 2,907 shares during the last quarter. Dimensional Fund Advisors LP raised its position in ImmuCell by 3.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 1,749 shares during the last quarter. Militia Capital Management LLC acquired a new position in ImmuCell in the first quarter worth $114,000. Mesirow Financial Investment Management Inc. boosted its stake in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares in the last quarter. Finally, Steadtrust LLC grew its holdings in shares of ImmuCell by 79.1% during the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock worth $349,000 after purchasing an additional 25,070 shares during the last quarter. Institutional investors own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.